Yantai Luye and Chengdu Biostar team up to bring cancer drug to market

Luye Pharma Group’s wholly-owned subsidiary, Yantai Luye Drugs Trading, has collaborated with Beijing Biostar Pharmaceuticals’ subsidiary, Chengdu Biostar Pharmaceuticals, to market an anticancer drug, Utidelone Injection, in mainland China.

Utidelone Injection, developed by Beijing Biostar Pharmaceuticals, is a new small molecule natural microbial anti-cancer drug which is a genetically modified derivative of epothilone.

It is a new non-taxane anticancer agent that targets microtubule polymerization.

As part of the collaboration, the companies will work together to promote the drug in 26 provinces on the Chinese mainland.

Last year, the National Medical Products Administration in China approved the marketing of Utidelone injection to treat patients with recurrent or metastatic advanced breast cancer.

Luye Pharma said Utidelone injection has been included in the Guidelines for Clinical Diagnosis and Treatment of Advanced Breast Cancer in China (2020 Edition).

It has also been included in the Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of breast cancer (the 2021 edition).

Chairman of Luye Pharma Group, Yang Rongbing, said, “In line with the ‘patient first’ philosophy, Luye Pharma is committed to addressing unmet patient needs. Oncology is one of our long-term strategic axes.

“We hope to help as many cancer patients as possible by increasing the breadth and depth of market coverage for Utidelone.

“This drug will help complement Luye Pharma’s oncology portfolio and increase the company’s strategic advantage in this area.

In addition, Utidelone is being evaluated in clinical studies for many new indications which include the treatment of many advanced solid tumors such as gastrointestinal cancers, head and neck cancers, cancer of the non-small cell lung and gynecological cancers.

Comments are closed.